Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma

Condition:   Esophageal Neoplasms
Interventions:   Radiation: IMRT simultaneous integrated boost;   Drug: Nimotuzumab;   Drug: Paclitaxel;   Drug: Nedaplatin;   Procedure: Esophagectomy
Sponsors:   Chinese Academy of Medical Sciences;   Hebei Medical University Fourth Hospital;   Affiliated Hospital of Hebei University;   Beijing Army General Hospital;   Beijing Hospital;   Peking University First Hospital;   Tianjin Medical University Cancer Institute and Hospital;   Henan Cancer Hospital;   The Affiliated Hospital of Inner Mongolia Medical University;   The First Affiliated Hospital with Nanjing Medical University;   Fujian Cancer Hospital
Recruiting - verified August 2016

from #ORL via xlomafota13 on Inoreader http://ift.tt/2aGhfG5
via IFTTT